Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Amylyx Pharmaceuticals
43 Thorndike St.
Cambridge, MA 02141
Phone: 617-571-8872
http://amylyx.com/

Amylyx is developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that target the neuroinflammation and nerve cell death that characterize these disorders. The company\'s therapeutic candidate, AMX0035, is a proprietary, fixed-dose combination therapy that blocks nerve cell death and neurotoxic inflammation.

Key Contact
Name
Joshua Cohen
Title
Co-Founder and CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
08/23/16 $5,000,000 Series A ALS Investment Fund
Henri Termeer
Morningside Venture
07/01/20 $30,000,000 Series B Morningside Group
07/20/21 $135,000,000 Series C 683 Capital Management
aMoon
Bain Capital Life Sciences
Falcon Edge Capital
Marshall Wace
Morningside Venture
Perceptive Advisors
Rock Springs Capital
Tybourne Capital Management
Verition Fund Management
Viking Global Investors
Woodline Partners


Featured Reading